Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Global Approach in Safety Testing - ICH Guidelines Explained

Global Approach in Safety Testing

ICH Guidelines Explained

van der Laan, Jan Willem, DeGeorge, Joseph J (Eds.)

2013, XII, 315 p. 15 illus., 13 illus. in color.

Available Formats:

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.


(net) price for USA

ISBN 978-1-4614-5950-7

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase

learn more about Springer eBooks

add to marked items


Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.


(net) price for USA

ISBN 978-1-4614-5949-1

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days

add to marked items

  • Written by experts who were involved in the ICH process
  • Provides state-of-the-art guidance
  • Guidelines serve as teaching tools

The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the US and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration. In Japan, the members are the Ministry of Health, Labour and Welfare (MHLW), and the Japan Pharmaceutical Manufacturers Association (JPMA). In Europe, the members are the EU (Representatives of the European Commission and the European Medicines Agency [EMA]), and the European Federation of Pharmaceutical Industries and Associations (EFPIA). In the United States, the members are the Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The International Federation of Pharmaceutical Manufacturers Associations (IFPMA)  is the secretariat of the ICH. Additional members include Observers from WHO, European Free Trade Association (EFTA), and Canada. The Observers represent non-ICH countries and regions.


This volume considers one of  ICH’s major categories, Safety,  covering topics relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.). Since the start of the ICH process, many guidelines have been written, but  in most cases  there is a lack of awareness of the many issues that were addressed during the development of the consensus guidances. Further, just as it is important to understand what the guidances state, it is also important to understand the thoughts, debates, and intent of the experts involved, which are not included in the guidance documents. Why has the guideline been written as it is written,  why are some topics ignored, and  why have some initial guidance proposals have  been deleted. These and other related questions and answers are the contents of this book, written by experts who were directly involved in writing the ICH guidances that drive drug development today.

Content Level » Research

Keywords » DeGeorge - Guideline - ICH - Laan - Safety

Related subjects » Biomedical Sciences - Pharmacology & Toxicology

Table of contents 

The  International Conference on Harmonisation. History of Safety Guidelines.- EU Perspective on ICH.- The Value and Benefits of the International Conference on Harmonisation (ICH) to Drug Regulatory Authorities Advancing Harmonization for Better Public Health.- A Japanese Perspective on Implementation of the Three Rs: Incorporating Best Scientific Practices into Regulatory Process.- Towards more Scientific Relevance in Carcinogenicity Testing.- The Evolution, Scientific Reasoning and Use of ICH S2 Guidelines for Genotoxicity Testing of Pharmaceuticals.- Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies , Where are we now; an  S3A/S3B update (1995-2011).- Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B).- Why and how did Reproduction Toxicity Testing make its early entry into and Rapid Success in ICH?.- ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.- Safety Pharmacology: Guidelines S7A and S7B.- ICH S8:  History and Perspectives.- ICH S9: Nonclinical Evaluation of Anticancer Pharmaceuticals a Perspective from Regulators on the Development of the Guideline.- Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals ICH M3 and M3(R2).

Popular Content within this publication 



Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Pharmaceutical Sciences / Technology.